Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QEQ278
- Development stage
- Phase 1
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
QEQ278 is an investigational intravenous drug candidate developed by Novartis for the treatment of advanced and metastatic solid tumors, including non-small cell lung cancer, esophageal squamous cell carcinoma, renal cell carcinoma, and human papilloma virus (HPV)-associated head and neck squamous cell carcinoma. It is currently being evaluated in phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in adult patients who have exhausted standard therapy options or are ineligible for them. The precise mechanism of action of QEQ278 has not been disclosed as of now.
02
Targets
NKG2DL (NKG2D ligand family)
Beyond the preview
Go deeper on QEQ278.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QEQ278.